Background/Aims: Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats. Methods: Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined. Results: Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group. Conclusion: These results demonstrate that terlipressin can inhibit the development of CIN.

Keywords:
Contrast-induced nephropathy, Terlipressin, Acute renal failure
1.
Mautone A, Brown JR: Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 2010;23:78–85.
2.
Sterling KA, Tehrani T, Rudnick MR: Clinical significance and preventive strategies for contrast-induced nephropathy. Curr Opin Nephrol Hypertens 2008;17:616–623.
3.
Bartorelli AL, Marenzi G: Contrast-induced nephropathy. J Interv Cardiol 2008;21:74–85.
4.
Rudnick M, Feldman H: Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008;3:263–272.
5.
Mehran R: Contrast-induced nephropathy remains a serious complication of PCI. J Interv Cardiol 2007;20:236–240.
6.
Al-Ghonaim M, Pannu N: Prevention and treatment of contrast-induced nephropathy. Tech Vasc Interv Radiol 2006;9:42–49.
7.
Van Praet JT, De Vriese AS: Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 2007;16:336–347.
8.
Schweiger MJ, Chambers CE, Davidson CJ, Blankenship J, Bhalla NP, Block PC, Dervan JP, Gasperetti C, Gerber L, Kleiman NS, Krone RJ, Phillips WJ, Siegel RM, Uretsky BF, Laskey WK: Prevention of contrast induced nephropathy: recommendations for the high risk patient undergoing cardiovascular procedures. Catheter Cardiovasc Interv 2007;69:135–140.
9.
Lameire NH: Contrast-induced nephropathy – prevention and risk reduction. Nephrol Dial Transplant 2006;21:i11–i23.
10.
Lebrec D: Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther 2004;20(suppl 3):65–67.
11.
Morelli A, Ertmer C, Pietropaoli P, Westphal M: Terlipressin: a promising vasoactive agent in hemodynamic support of septic shock. Expert Opin Pharmacother 2009;10:2569–2575.
12.
Pesaturo AB, Jennings HR, Voils SA: Terlipressin: vasopressin analog and novel drug for septic shock. Ann Pharmacother 2006;40:2170–2177.
13.
Singer M: Arginine vasopressin vs. terlipressin in the treatment of shock states. Best Pract Res Clin Anaesthesiol 2008;22:359–368.
14.
Fabrizi F, Dixit V, Messa P, Martin P: Terlipressin for hepatorenal syndrome: a meta-analysis of randomized trials. Int J Artif Organs 2009;32:133–140.
15.
Sagi SV, Mittal S, Kasturi KS, Sood GK: Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol 2010;25:880–885.
16.
Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F: Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007;46:1863–1871.
17.
Narahara Y, Kanazawa H, Taki Y, Kimura Y, Atsukawa M, Katakura T, Kidokoro H, Harimoto H, Fukuda T, Matsushita Y, Nakatsuka K, Sakamoto C: Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis. J Gastroenterol Hepatol 2009;24:1791–1797.
18.
Magan AA, Khalil AA, Ahmed MH: Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists. World J Gastroenterol 2010;16:5139–5147.
19.
Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941–948.
20.
Kiemer AK, Fürst R, Vollmar AM: Vasoprotective actions of the atrial natriuretic peptide. Curr Med Chem Cardiovasc Hematol Agents 2005;3:11–21.
21.
Tahara A, Saito M, Tsukada J, Ishii N, Tomura Y, Wada K, Kusayama T, Yatsu T, Uchida W, Tanaka A: Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells. Eur J Pharmacol 1999;368:89–94.
22.
Doi K, Noiri E, Fujita T: Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol 2010;8:122–128.
23.
Huang YT, Lin LC, Chern JW, Lin HC, Hong CY: Portal hypotensive effects of combined terlipressin and DL-028, a synthetic alpha 1 adrenoceptor antagonist administration on anesthetized portal hypertensive rats. Liver 1999;19:129–134.
24.
Ioannou G, Doust J, Rockey DC: Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003;1: CD002147.
25.
Agmon Y, Peleg H, Greenfield Z: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994;94:1069–1075.
26.
Toprak O, Cirit M, Tanrisev M, Yazici C, Canoz O, Sipahioglu M, Uzum A, Ersoy R, Sozmen EY: Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008;23:853–859.
27.
Wang YX, Jia YF, Chen KM, Morcos SK: Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001;74:1103–1108.
28.
Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH: Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 2007;117:3810–3820.
29.
Kagan A, Sheikh-Hamad D: Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin Cardiol 2010;33:62–66.
30.
Persson PB, Hansell P, Liss P: Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14–22.
31.
Moore E, Bellomo R, Nichol A: Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol 2010;76:425–440.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.